“These new rules are unduly onerous, expensive, and impractical. Even if they are ultimately implemented, it is unlikely that they would greatly facilitate clinical cannabis research in the United States.”
Authors reported that patients administered oral THC experienced a “nine-fold greater reduction in opioid consumption” compared to controls.
The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine.
Researchers reported: “For the first time, we show a statistically significant negative association between recreational access to cannabis and OTC sleep aid sales.”
Occasional cannabis use during late adolescence is not independently associated with adverse effects on cognitive abilities in young adulthood, according to study.
Patients suffering from persistent pain conditions who frequently use cannabis are far less likely to use non-prescription opioids, according to study.
Investigators lab-tested 30 CBD products obtained from leading online retailers. Twenty of the thirty products possessed significant deviations in CBD content as compared to what was advertised. Sixteen of the 20 products contained lower percentages of CBD than the amount stated on the product’s label.
“Individuals who report having pain limiting that limits their daily activity see large health improvements. This is the strongest evidence that a group with a high probability of pain medication use sees large benefits from medical marijuana laws.”